VSee Health, Inc. (VSEE) Targets Doubling Revenue in 2027, Plans OTCQB Move

VSee Health (NASDAQ:VSEE) said it signed a non-binding letter of intent to acquire healthcare technology and operating assets for a vertically integrated healthcare commerce platform. VSee estimates the deal value at about $42 million, with target annualized revenue over $35 million and about $7 million EBITDA, unaudited. Closing depends on due diligence, definitive agreements, and approvals.

VSee Health, Inc. signed a non-binding LOI to acquire healthcare technology and operating assets valued at about $42 million. The target supports a clinic-based wellness commerce platform with an unaudited annual revenue run rate over $35 million and about $7 million in EBITDA. VSee says it would integrate ordering and payment workflows into its API virtual care platform, subject to due diligence and approvals.

VSee Health (NASDAQ:VSEE) said it entered a non-binding letter of intent to acquire certain healthcare technology and operating assets for a vertically integrated healthcare commerce platform. The target assets have an unaudited run rate above $35 million and EBITDA around $7 million. VSee expects a quick close without initial shareholder dilution, subject to due diligence and definitive agreements.

VSee Health (NASDAQ:VSEE) said it entered a non-binding letter of intent to acquire certain healthcare technology and operating assets for $42 million. The target assets have an unaudited run rate above $35 million in annualized revenue and about $7 million in EBITDA. VSee will conduct due diligence and negotiate definitive terms; no deal is assured.

VSEE HEALTH, INC. (VSEE) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.1 3 vseeex99-1.htm EXHIBIT 99.1 Exhibit 99.1 VSEE HEALTH, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On May 31, 2026, VSee Health, Inc., a Delaware corporation (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with

Eli Lilly is investing $5bn in a new production site in Virginia, part of a $50bn plan to expand US drug manufacturing. The facility will be the company's first fully integrated plant, producing both APIs and finished drugs. It is the tenth new US site since 2020.